Annual report for Jagsonpal Pharmaceuticals Ltd. for FY-2023
23-05-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Consider And Approve, Inter-Alia: A) The Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2023. B) Recommendation Of Dividend, If Any, For The Financial Year Ended March 31, 2023.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 ,inter alia, to consider and approve a) the Audited Financial Results of the Company for the quarter and year ended March 31, 2023. b) recommendation of dividend, if any, for the financial year ended March 31, 2023.15-05-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company JAGSONPAL PHARMACEUTICALS LTD. 2 CIN NO. L74899DL1978PLC009181 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-23, 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Abhishek JoshiDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Salapaka Venkata Subha Rao Designation : -Chief Financial Officer Date: 28/04/202328-04-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyJAGSONPAL PHARMACEUTICALS LTD. 2CIN NO.L74899DL1978PLC009181 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Abhishek Joshi Designation: Compliance Officer EmailId: abhishek.joshi@jagsonpal.com Name of the Chief Financial Officer: Salapaka Venkata Subha Rao Designation: Chief Financial Officer EmailId: svrao@jagsonpal.com Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-04-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 we are enclosing herewith a copy of the certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended March 31, 2023. We request you to take the above on record.18-04-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Submission Of Certificate From A Practicing Company Secretary Under Regulation 40(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
We hereby submit certificate received from Practicing Company Secretary under regulation 40 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended March 31, 2023. We request you to take the above on record.18-04-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Submission Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 7(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Compliance Certificate jointly executed by the authorized representative of our share transfer agent viz. MCS Share Transfer Agent Limited and the Compliance Officer of Jagsonpal Pharmaceuticals Limited for the year ended March 31, 2023. We request you to take the above on record.18-04-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Closure of Trading Window
In terms of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company''s Code of Conduct to regulate, monitor and report trading by designated persons & immediate relatives of Designated Persons, the Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") shall remain closed for Designated Persons and their immediate relative(s) with effect from Saturday, April 1, 2023 till the end of 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2023. The date of the Meeting of Board of Directors of the Company at which the aforesaid Financial Results are to be approved, will be intimated to the Stock Exchanges in due course.31-03-2023
JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Materiality Policy - List Of Authorised Persons
We wish to inform you that consequent to the appointment of Mr. Abhishek Joshi as Company Secretary, the Board of Directors have approved changes in KMPs authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) under the Listing Regulations. The contact details of the KMPs authorized is as under: Name of KMP Designation Mr. Manish Gupta Managing Director Mr. S.V. Subha Rao Chief Financial Officer Mr. Abhishek Joshi Company Secretary Contact details Tel No. 0124 - 4406710 Email id: cs@jagsonpal.com13-02-2023